Myovant Squares Off with AbbVie On Endometriosis Treatment

Myovant Sciences (NYSE:MYOV) fired a shot across the bow of AbbVie (NYSE:ABBV) when it released phase 3 clinical trial results on April 22. The study evaluating relugolix as a treatment for pain caused by endometriosis met two co-primary endpoints and a slate of secondary endpoints. Relugolix has clearly pointed its crosshairs on AbbVie's Orilissa, approved by the Food and Drug Administration (FDA) in 2018.